February 17, 2022
Bob Discordia Joins CaaMTech as Chief Scientific Officer
Dr. Discordia brings over 30 years of pharmaceutical industry experience to CaaMTech
February 17, 2022
Dr. Discordia brings over 30 years of pharmaceutical industry experience to CaaMTech
November 16, 2021
Scientists will assess the potential of psychedelic compounds for treating addiction
September 15, 2021
Serotonin is a tryptamine-based human neurotransmitter responsible for a variety of complex biological functions
September 8, 2021
CaaMTech, Inc., a leading psychedelic drug discovery company, has today announced the completion of a $22 million Series A financing …
May 3, 2021
Dr. Andrew Chadeayne will speak about filling the unmet need for pure, well-characterized tryptamines
April 13, 2021
5-MeO-DPT is a structural analog of 5-MeO-DMT, the “God molecule”
March 22, 2021
5-MeO-DALT fumarate is the latest novel compound from CaaMTech and UMass Dartmouth’s Manke Lab
March 10, 2021
CaaMTech’s latest published patent application covers important, yet understudied tryptamine compounds
February 10, 2021
CaaMTech’s first of over one hundred patent applications is nearing the finish line
February 5, 2021
CaaMTech’s synthesizes another important Bufo alvarius toad secretion compound